ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias

Eczema trials near Taipei City, TWN:

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...

Active, not recruiting
Atopic Dermatitis
Drug: Topical corticosteroid
Drug: Baricitinib

Phase 3

Lilly
Lilly

Taipei, Taiwan and 78 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Taipei City, Taipei, Taiwan and 98 other locations

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Eczema
Atopic Dermatitis
Drug: Lebrikizumab
Drug: Placebo

Phase 3

Lilly
Lilly

Taipei, Taiwan and 96 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 557 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Taipei, Taiwan and 320 other locations

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and...

Enrolling
Atopic Dermatitis
Drug: GM-XANTHO onitment
Drug: Placebo onitment

Phase 1, Phase 2

Xantho Biotechnology

Taipei, Taiwan and 3 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Taipei, Taiwan and 454 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Taipei City, Taiwan and 195 other locations

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

Phase 2

Lilly
Lilly

Taipei City, Taipei, Taiwan and 67 other locations

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib

Phase 4

AbbVie
AbbVie

Taipei City, Taiwan and 106 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems